VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 3, 2006, Pages 836-841

  Brazelle, William D ^a   Shi, Wenyin ^a   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Colorectal cancer; Fractionated radiotherapy; VEGF targeting; ZD6474

Indexed keywords

CARCINOGENS; FRACTIONATION; MATHEMATICAL MODELS; RADIATION; RADIOTHERAPY; TUMORS;

CLINICAL TRIAL EVALUATION; COLORECTAL CANCER; ENDOTHELIAL GROWTH; FRACTIONATED RADIOTHERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) TARGETING;

ENZYME INHIBITION;

PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; VANDETANIB; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CANCER RADIOTHERAPY; CELL STRAIN HT29; COLORECTAL CARCINOMA; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; FEMALE; HT29 CELLS; HUMANS; MICE; MICE, INBRED STRAINS; MICE, NUDE; PIPERIDINES; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RADIOTHERAPY DOSAGE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33646915238     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.02.023     Document Type: Article

References (41)

1. Ausprunk D.H., and Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14 (1977) 53-65
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (2002) 15-18
3. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 3 (2003) 643-651
4. Tammela T., Enholm B., Alitalo K., et al. The biology of vascular endothelial growth factors. Cardiovasc Res 65 (2005) 550-563
5. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 94 (2005) 209-231
6. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
7. Xie K., Wei D., Shi Q., et al. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 15 (2004) 297-324
8. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor. A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20 (2002) 4368-4380
9. Lee C.G., Heijn M., di Tomaso E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60 (2000) 5565-5570
10. Geng L., Donnelly E., McMahon G., et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61 (2001) 2413-2419
11. Gorski D., Beckett M.A., Jaskowiak N., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
12. Hess C., Vuong V., Hegyi I., et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85 (2001) 2010-2016
13. Fayette J., Soria J.C., and Armand J.P. Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 41 (2005) 1109-1116
14. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 Suppl. 1 (2004) 2-10
15. Hudis C.A. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 19 (2005) 26-31
16. Jain R.K. Antiangiogenic therapy for cancer. Current and emerging concepts. Oncology (Williston Park) 19 (2005) 7-16
17. Lenz H.J. Antiangiogenic agents in cancer therapy. Oncology (Williston Park) 19 (2005) 17-25
18. Siemeister G., Martiny-Baron G., and Marme D. The pivotal role of VEGF in tumor angiogenesis. Molecular facts and therapeutic opportunities. Cancer Metastasis Rev 17 (1998) 241-248
19. Witte L., Hicklin D.J., Zhu Z., et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 17 (1998) 155-161
20. McMahon G. VEGF receptor signaling in tumor angiogenesis. The Oncologist 5 Suppl. 1 (2000) 3-10
21. Gille H., Kowalski J., Li B., et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276 (2001) 3222-3230
22. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62 (2002) 7284-7290
23. Ciardiello F., Caputo R., Damiano V., et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9 (2003) 1546-1556
24. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62 (2002) 4645-4655
25. Bates D. ZD-6474. AstraZeneca. Curr Opin Investig Drugs 4 (2003) 1468-1472
26. Miller K.D., Trigo J.M., Wheeler C., et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11 (2005) 3369-3376
27. Siemann D.W., and Horsman M.R. Targeting the tumor vasculature. A strategy to improve radiation therapy. Expert Rev Anticancer Ther 4 (2004) 321-327
28. DeVita V., Hellman S., and Rosenberg S. Cancer. Principles and practice of oncology (1997), Lippincott Raven, Philadelphia 307-332
29. Shi W., Teschendorf C., Muzyczka N., et al. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol 66 (2003) 1-9
30. Ng H.K.T., and Balakrishnan N. Wilcoxon-type rank-sum precedence tests. Austral N Z J Stat 46 (2004) 631-648
31. Shi W., and Siemann D.W. Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br J Cancer 87 (2002) 119-126
32. Williams K.J., Telfer B.A., Brave S., et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy. Schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10 (2004) 8587-8593
33. Shi W., and Siemann D.W. Targeting the tumor vasculature. Enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 19 (2005) 1045-1050
34. Zips D., Krause M., Hessel F., et al. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res 23 (2003) 3869-3876
35. Rusnak D.W., Affleck K., Cockerill S.G., et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors. Potential therapy for cancer. Cancer Res 61 (2001) 7196-7203
36. Gong H., Pottgen C., Stuben G., et al. Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth. Potentiation by irradiation. Int J Cancer 106 (2003) 723-728
37. Tong R.T., Boucher Y., Kozin S.V., et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64 (2004) 3731-3736
38. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy. A new paradigm for combination therapy. Nat Med 7 (2001) 987-989
39. Kermani P., Leclerc G., Martel R., et al. Effect of ionizing radiation on thymidine uptake, differentiation, and VEGFR2 receptor expression in endothelial cells. The role of VEGF(165). Int J Radiat Oncol Biol Phys 50 (2001) 213-220
40. Wachsberger P., Burd R., and Dicker A. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents. Exploring mechanisms of interaction. Clin Cancer Res 9 (2003) 1957-1971
41. Longo R., Sarmiento R., Fanelli M., et al. Anti-angiogenic therapy. Rationale, challenges, and clinical studies. Angiogenesis 5 (2002) 237-256